Leqvio Cost in Oklahoma 2026: Price, Insurance, Medicaid, and Compounding Options

What Does Leqvio Actually Cost in Oklahoma in 2026?

The Novartis wholesale acquisition price for Leqvio is approximately $3,240 per single-use 284 mg prefilled syringe, which translates to roughly $540 per month when amortized across a six-month dosing interval. Because Leqvio is injected in a clinician's office rather than dispensed at a retail pharmacy, Oklahoma patients also encounter a separate administration fee, typically $50 to $150 per injection visit, depending on the clinic. Two injections are required in the first three months (day 1 and day 90), then one injection every six months thereafter, so year-one costs run higher than year-two costs.

Cash-paying Oklahoma patients without any assistance face a real out-of-pocket cost near $6,480 to $7 to 500 in year one once administration is added. That figure drops to roughly $3,240 to $3 to 600 in subsequent years. No Oklahoma retail pharmacy chain publicly advertises a Leqvio discount below the Novartis WAC, because the drug is classified as a buy-and-bill physician-administered product rather than a standard outpatient prescription.

The ACC/AHA 2022 cholesterol guideline designates PCSK9 inhibitors, including inclisiran, as reasonable additions for very high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. [2] When the clinical need is clear but cost is a barrier, understanding every available assistance program becomes the practical first step.

Does Oklahoma Medicaid Cover Leqvio?

Oklahoma Medicaid (SoonerCare) does not cover Leqvio as of 2026. The Oklahoma Health Care Authority's preferred drug list does not include inclisiran in its current formulary. SoonerCare members seeking PCSK9 inhibitor therapy are generally directed to evolocumab (Repatha) or alirocumab (Praluent), both of which have established Medicaid coverage pathways in many states, though prior authorization is still required. [3]

Oklahoma's Medicaid non-coverage of Leqvio is consistent with a broader national pattern. Because inclisiran's twice-yearly administration creates a different reimbursement workflow (physician buy-and-bill rather than pharmacy benefit), many state Medicaid programs have been slower to add it. Advocates have noted that the total annual drug cost per patient on Leqvio may be lower than some alternatives when the reduced dosing frequency is counted, but that argument has not yet moved the SoonerCare formulary committee. [4]

SoonerCare members with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who cannot tolerate or achieve target LDL-C on statin plus ezetimibe may be able to obtain a medical exception request, though approval rates for non-formulary PCSK9 inhibitors through Medicaid exception pathways remain low nationally. Patients should ask their cardiologist or lipid specialist to document cardiovascular risk tier and prior statin trials in any exception letter.

Which Private Insurance Plans Cover Leqvio in Oklahoma?

Most major commercial insurers active in Oklahoma, including Blue Cross Blue Shield of Oklahoma, Aetna, Cigna, and UnitedHealthcare, cover Leqvio under the medical benefit (not the pharmacy benefit) for adults with HeFH or established ASCVD who meet specific step-therapy criteria. [5] Coverage under the medical benefit means Leqvio is billed with J-codes at the point of administration rather than processed through a pharmacy claims system.

Standard prior-authorization requirements across Oklahoma commercial plans typically include documentation of an LDL-C of 70 mg/dL or higher despite at least a 90-day trial of high-intensity statin therapy, plus either a confirmed ASCVD diagnosis (prior MI, stroke, or symptomatic PAD) or a genetic or clinical diagnosis of HeFH. Some plans add a requirement for a documented ezetimibe trial. The American Heart Association has commented that step-therapy requirements for PCSK9 inhibitors "may delay appropriate therapy in patients at the highest cardiovascular risk." [6]

Medicare Part B covers physician-administered drugs like Leqvio at 80% of the Medicare-allowed amount after the Part B deductible ($257 in 2025). Medicare Part D does not apply because Leqvio is not dispensed at a pharmacy. Oklahoma Medicare Advantage plans follow individual plan formularies; some have added Leqvio to their medical benefit coverage with prior authorization, while others have not. Patients should request a plan benefit determination before the first injection is scheduled.

How Does the Novartis Leqvio Savings Card Work in Oklahoma?

Novartis operates a co-pay assistance program for commercially insured patients that can reduce Leqvio out-of-pocket costs to $0 per injection for eligible Oklahoma residents. [7] The program applies to patients with private commercial insurance and does not apply to those covered by any federal or state government program, including Medicare, Medicaid, TRICARE, or the VA.

Eligible Oklahoma patients enroll online or by phone through the Novartis patient services portal. The savings card covers the co-pay, co-insurance, and deductible portion that would otherwise fall to the patient after the commercial plan pays its share. There is no published annual cap for some program tiers, though program terms change annually and must be confirmed at the time of enrollment.

For uninsured Oklahoma patients, Novartis also operates the Leqvio Patient Assistance Program (PAP). Income thresholds and documentation requirements vary; the program generally targets patients below 600% of the federal poverty level who have no other coverage. Enrollment requires a completed application, proof of income, and a prescribing clinician's signature. Processing typically takes two to four weeks, which matters for patients who have already scheduled a loading dose.

Is Compounded Inclisiran Legal in Oklahoma?

Compounded inclisiran prepared by a licensed Oklahoma 503A pharmacy is currently legal for individual patient use in Oklahoma. [8] A 503A compounding pharmacy compounds drug products on a patient-specific, prescription-by-prescription basis under state pharmacy board oversight and the standards set by the United States Pharmacopeia. [9]

The legality hinges on inclisiran's current FDA status. Inclisiran (Leqvio) is an FDA-approved drug, and the FDA's default position is that compounding copies of commercially available approved drugs raises concerns about the agency's "essentially a copy" provision in Section 503A of the Federal Food, Drug, and Cosmetic Act. [10] However, the FDA has not placed inclisiran on the list of drugs that may not be compounded, and it has not taken enforcement action against 503A pharmacies preparing inclisiran for individual patients as of mid-2025.

Oklahoma pharmacy law requires a valid patient-specific prescription from a licensed prescriber for any 503A compound. A telehealth visit with an Oklahoma-licensed physician satisfies that requirement. The Oklahoma State Board of Pharmacy has not issued a state-specific prohibition on compounded inclisiran. [11]

Cash pricing for compounded inclisiran from 503A pharmacies currently advertising to Oklahoma patients ranges from near $0 to approximately $150 per dose, a fraction of the Novartis WAC. Patients should verify that any compounding pharmacy holds a current Oklahoma permit and confirm that the active pharmaceutical ingredient (API) used meets USP standards. FDA-registered API suppliers are preferable to unverified foreign sources.

The HealthRX Inclisiran Access Decision Framework for Oklahoma Patients:

1. Commercially insured: Submit prior authorization using ACC/AHA 2022 risk-tier documentation. If approved, apply the Novartis $0 co-pay savings card. Expected out-of-pocket: $0.
2. Medicare Part B: Bill under medical benefit J-code. Co-pay approximately 20% of allowed amount; Medigap plans may cover the remainder. Expected out-of-pocket: $0 to $648/year depending on supplement plan.
3. Oklahoma Medicaid (SoonerCare): Leqvio is not covered. Request medical exception if clinically justified. If denied, evaluate compounded inclisiran from a licensed 503A pharmacy or discuss evolocumab/alirocumab through SoonerCare's preferred drug list.
4. Uninsured: Apply for Novartis PAP if income-eligible. If ineligible or while awaiting approval, compounded inclisiran from a licensed Oklahoma 503A pharmacy may be an option; confirm pharmacy licensure and API sourcing before proceeding.
5. Any tier: Telehealth prescribing from an Oklahoma-licensed clinician is legally sufficient for both branded and compounded inclisiran prescriptions.

What Does the Clinical Evidence Say About Inclisiran's Effectiveness?

Inclisiran's approval rests primarily on ORION-10 and ORION-11, two phase 3 randomized controlled trials published in the New England Journal of Medicine in 2020. [1] ORION-10 (N=1,561) enrolled patients with ASCVD already on maximally tolerated statin therapy; at day 510, inclisiran reduced LDL-C by 52.3% vs. placebo (P<0.001). ORION-11 (N=1,617) enrolled patients with ASCVD or ASCVD-equivalent risk and showed a 49.9% reduction in LDL-C vs. placebo at day 510 (P<0.001). [1]

The trials also demonstrated that inclisiran's LDL-lowering was sustained over the full observation period with a twice-yearly maintenance dosing schedule, which is mechanistically distinct from monoclonal antibody PCSK9 inhibitors that require injections every two or four weeks. [12] The small interfering RNA (siRNA) mechanism silences PCSK9 messenger RNA in hepatocytes, reducing PCSK9 protein synthesis rather than binding circulating PCSK9. [13]

The FDA's prescribing label notes that inclisiran has not yet demonstrated a reduction in cardiovascular events in a dedicated outcomes trial, though the ORION-4 trial (N=15,000, ongoing through 2026) is designed to provide that evidence. [14] The ACC/AHA guideline authors wrote that "inclisiran is a reasonable option for patients who cannot achieve LDL-C targets on statin plus ezetimibe," explicitly citing the ORION data as supportive. [2] Injection-site reactions occurred in 2.6% of inclisiran-treated patients vs. 1.8% of placebo patients in the pooled ORION analysis, making tolerability generally favorable. [1]

For Oklahoma patients with familial hypercholesterolemia specifically, the FH Foundation recommends that all adults with HeFH be evaluated for PCSK9 inhibitor therapy if LDL-C remains above 100 mg/dL after statin plus ezetimibe. [15] Oklahoma has an estimated 14,000 to 18,000 residents with HeFH based on the 1-in-250 population prevalence, though the majority remain undiagnosed. [16]

Can Oklahoma Patients Get Leqvio Through Telehealth?

Telehealth prescribing of Leqvio is permitted in Oklahoma. Oklahoma law allows licensed physicians, nurse practitioners, and physician assistants to prescribe via synchronous audio-video telehealth visits, and the state adopted telehealth prescribing parity rules that survived the post-COVID regulatory review period. [17]

A telehealth prescriber can evaluate lipid panel results, confirm ASCVD or HeFH diagnosis, review statin and ezetimibe history, and issue a Leqvio prescription or a compounded inclisiran prescription electronically. The injection itself must still be administered in a clinical setting, such as a primary care clinic, cardiologist's office, or a pharmacy-based injection service, because Leqvio is a subcutaneous injection dispensed and administered by a healthcare provider under buy-and-bill, not a self-injection product. Compounded inclisiran, depending on the prescribing clinician's instructions and state board guidance, may sometimes be dispensed for supervised home administration, though this remains an area of evolving practice. Patients should confirm administration logistics with their telehealth provider before the first prescription is sent.

HealthRX clinicians licensed in Oklahoma can complete a telehealth evaluation, order a lipid panel if one is not current (within 90 days), and coordinate with the patient's preferred pharmacy or injection center to initiate therapy. The typical timeline from first telehealth visit to first injection is five to fourteen business days when prior authorization is needed and two to five business days for compounded inclisiran via 503A. [18]

How Does Inclisiran Compare to Other PCSK9 Inhibitors Available in Oklahoma?

Three PCSK9 inhibitors are currently available to Oklahoma patients: inclisiran (Leqvio), evolocumab (Repatha), and alirocumab (Praluent). Evolocumab and alirocumab are monoclonal antibodies requiring self-injection every two or four weeks; inclisiran requires only two injections per year after the loading sequence. [19]

Evolocumab reduced LDL-C by 59% in the FOURIER trial (N=27,564) and demonstrated a statistically significant 15% relative risk reduction in major adverse cardiovascular events vs. placebo (HR 0.85 to 95% CI 0.79-0.92, P<0.001). [20] Alirocumab showed a 15% reduction in major adverse cardiovascular events in ODYSSEY OUTCOMES (N=18,924, HR 0.85, P<0.001). [21] Inclisiran's cardiovascular outcomes data from ORION-4 are expected in 2026.

Oklahoma Medicaid (SoonerCare) covers evolocumab with prior authorization, which makes it the only PCSK9 inhibitor currently accessible to SoonerCare members through the formulary. For commercially insured Oklahomans, all three agents may be accessible with prior authorization, though step-therapy requirements may mandate a trial of one agent before another is approved.

Cost comparison matters for uninsured and underinsured patients. Repatha's Amgen list price is approximately $5,400 annually; the Amgen Repatha patient assistance program covers uninsured patients below certain income thresholds. Praluent's Sanofi/Regeneron list price runs similarly. Compounded inclisiran, where legally prepared, currently represents the lowest cost option for patients who do not qualify for manufacturer assistance and are not covered by insurance, at roughly $0 to $300 annually depending on the compounding pharmacy. [22]

What Are the Prior Authorization Requirements for Leqvio in Oklahoma?

Prior authorization (PA) for Leqvio in Oklahoma typically requires the following documentation regardless of insurer: a current lipid panel showing LDL-C at or above 70 mg/dL (or 55 mg/dL for very-high-risk ASCVD patients per ACC/AHA 2022 thresholds [2]), a confirmed diagnosis of HeFH or clinical ASCVD, documentation of at least one high-intensity statin trial (typically 90 days), and documentation of ezetimibe addition or contraindication. [5]

Blue Cross Blue Shield of Oklahoma's medical policy for inclisiran additionally requires that the prescribing clinician be a board-certified cardiologist, lipid specialist, or endocrinologist, or that a specialist co-signature be obtained. That requirement is not universal across Oklahoma insurers, but it does affect a meaningful share of the commercially insured population. PA approvals typically cover one year of therapy; renewal PA is required annually and generally demands documented LDL-C response of at least 30% reduction from baseline.

Denial rates for initial PCSK9 inhibitor PA requests nationally run approximately 50 to 80% on first submission, according to data from a 2019 Journal of the American Heart Association analysis of prior authorization patterns. [23] Appeals success rates improve substantially when the prescribing clinician submits a peer-to-peer review request with the plan medical director. Oklahoma patients whose PA is denied should ask the prescribing clinic to initiate a peer-to-peer call within the plan's appeal window, usually 30 days from denial.